Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-1/PD-L1-IN-27 is a potent inhibitor of PD-1/PD-L1, exhibiting an IC50 of 134 nM and demonstrating antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,520.00 | |
50 mg | 8-10 weeks | $ 1,980.00 | |
100 mg | 8-10 weeks | $ 2,500.00 |
Description | PD-1/PD-L1-IN-27 is a potent inhibitor of PD-1/PD-L1, exhibiting an IC50 of 134 nM and demonstrating antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1]. |
In vitro | PD-1/PD-L1-IN-27 (compound MZ58) administered at concentrations of 2.5, 5, 10, and 50 µM for 48 hours demonstrates antitumor activity while maintaining low cytotoxicity towards T cells [1]. |
In vivo | PD-1/PD-L1-IN-27, administered intragastrically at dosages of 10 and 25 mg/kg, exhibits an antitumor effect [1]. |
Molecular Weight | 673.75 |
Formula | C44H35NO6 |
CAS No. | 2891831-47-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-1/PD-L1-IN-27 2891831-47-1 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 inhibitor inhibit